Background
Breast cancer is the most commonly diagnosed cancer and the leading cause of tumor-related mortality in women worldwide [
1]. Nearly 20–30% of patients with early-stage breast cancer experience local or distant recurrence even after standard loco-regional and adjuvant treatments [
2]. Although great efforts have been made to identify prognostic biomarkers for risk stratification [
3‐
6], the biological underpinnings of the recurrence are still poorly characterized, and predictive biomarkers leading to individualized treatments in the recurrence setting are still needed.
Large-scale next-generation sequencing technologies have provided valuable insights into the genomic landscape of breast cancers. The most recurrent alterations affect
PIK3CA and
TP53 genes.
CCND1 copy number gain is more frequent in estrogen receptor (ER)-positive breast cancer.
MYC amplification and homologous recombination deficiency, including
BRCA1 pathogenic variants, have been reported more frequently in triple negative (ER−/PR−/HER2−) tumors [
7,
8].
FGFR1 amplification has been associated with poor prognosis in hormone receptor-positive, lymph node-positive breast cancers [
9].
HER2 amplification [
10] or
PIK3CA and
ESR1 mutations [
11‐
13] have been linked to response to therapy. However, a heterogeneous spectrum of driver alterations characterizes the molecular portrait of invasive breast tumors and their clinical implications remain to be fully elucidated.
The dynamic evolution of the breast cancer genome from pre-invasive stages to metastasis is ruled by phenomena of spatial and temporal heterogeneity [
14]. Spatial heterogeneity can involve distinct areas within a tumor causing differences at morphologic, genomic, transcriptomic, and proteomic levels. Temporal heterogeneity indicates the variations between primary and metastasis caused by the metastatic process itself as well as the therapeutic interventions administered. Therefore, given the intra-tumor genetic heterogeneity, a clonal selection event, as well as the onset of additional alterations, may occur during tumor evolution over time or in response to therapy.
In this study, we analyzed a single-institution cohort of 128 patients with early-stage breast cancer and at least one (regional or distant) recurrence in 17 years. We performed comprehensive genomic profiling of primary and matched relapsed tumors aiming to (i) define the repertoire of genetic alterations of primary and metastatic/recurrent breast cancers and (ii) their association with specific clinico-pathological features and (iii) identify additional and potentially actionable alterations in the metastasis/recurrence site.
Discussion
In the present study, we performed a comprehensive genomic profile of 106 primary breast cancers and 82 recurrences, including 70 cases with matched primary and relapse samples. We identified specific molecular characteristics of primary tumors associated with time to relapse. Moreover, we showed that a backbone of recurrent driver molecular alterations of primary tumors was retained in the recurrences. However, additional private genomic aberrations were detected in relapse samples, including clinically relevant genes and potentially actionable targets.
Overall, more than 95% of the specimens under investigations, including both primary and recurrences, harbored at least one driver mutation, with a median number of three driver alterations per sample. As previously reported in larger series [
24,
25], we found heterogeneous genomic profiles, with few recurrent molecular aberrations, including mutations of
TP53 and
PIK3CA and copy number gains
MYC,
CCND1,
FGF19,
FGF3, and
FGFR1. Specific alterations were significantly associated with breast cancer subtypes in both primary tumors and recurrences.
TP53 and
NF1 mutations were more frequently identified in triple negative breast cancers whereas
CCND1,
FGF3,
FGF19,
ESR1, and
FGFR1 copy number gains were recurrent in tumors of luminal subtype. In this latter group, a significant association between
ESR1 alterations and recurrence was seen, probably reflecting the mechanism of acquired resistance to endocrine therapies [
26].
TP53 mutations and
MYC copy number gains in primary tumors were significantly associated with the time to relapse. This association was retained in the multivariable analysis adjusted for known prognostic factors. The clinical value of somatic
TP53 mutations has been largely evaluated according to a specific mutation type, protein domain involved, gene expression data (i.e., PAM 50), and hormone receptor status [
27‐
29]. Moreover, MYC deregulation plays a critical role in cell proliferation and tumor progression, and it has been associated with an aggressive clinical behavior and poor prognosis in breast cancer [
30‐
35]. As previously reported [
36], our data suggest that
MYC and
TP53 alterations may represent independent poor prognostic factors in early-stage breast cancer. Moreover, an increased number of total mutations in primary tumors could be associated with a shorter time to relapse. Even if different NGS panels have been used in this study and the data should be further validated, these findings are consistent with the observation that a high tumor mutation burden may correlate with a poor prognosis in various cancer types [
37‐
39].
To focus on the dynamic evolution of breast cancer genome, we firstly compared the overall data between primary and recurrence tumors. A trend of an increasing number of driver alterations of breast cancer-related genes was observed in recurrence samples as compared to primary tumors, including alterations in
FGFR1,
ESR1,
NF1,
BRCA1, and
PTEN genes. These data may have a clinical impact since the additional burden of alterations included actionable or druggable genes [
13,
40,
41] or genes related to therapy resistance. In particular,
NF1 alterations have been reported in association with endocrine therapy resistance in lobular breast cancer [
42]. Recently, Pearson et al. showed that
NF1 mutations were frequently acquired in breast cancer at progression and were associated with shorter survival in hormone receptor-positive breast cancers relapsing during adjuvant endocrine therapy [
43]. However, in our series, mutations of
NF1 were more frequently detected in tumors of triple negative subtype. Further studies are needed to confirm these findings and to unveil the biological and clinical significance of this alteration in triple negative breast cancers.
We evaluated in detail the evolution of breast cancer biology at the single patient level with the analysis of matched primary and relapse samples. Molecular subtype changes from primary tumors to recurrences were seen in 7.8% of cases. These proportions were lower but consistent with previously reported meta-analysis data of larger cohorts [
44‐
51]. We observed a high level of concordance (55.8%) of genomic aberrations between primary and matched relapse specimens. However, the proportion of shared aberrations was lower in cases with later recurrence (49.3%). Indeed, Yates and colleagues showed that the number of mutations was similar in primary and synchronous metastasis but a high number of mutations accumulated during breast cancer evolution and can be detected in samples from late relapses [
52]. Moreover, 63.9% of cases had private alterations in their recurrence, including 19.7% of patients with clinically actionable aberrations (e.g., affecting
ERBB2,
BRCA2,
PIK3CA) that may be targeted by available biological drugs [
23].
This study has several limitations. First, given the failure rate of NGS performed on nucleic acids extracted from old FFPE samples, we were able to evaluate only 65.1% of the cases. As known, stringent NGS quality metrics are needed to obtain robust results when long-term stored FFPE specimens are investigated. In our cohort, 73 (25.3%) specimens had an archival time longer than 10 years, and 79 (27.3%) cases longer than 5 years. Second, using two different NGS panels (FoundationOne and Oncomine Comprehensive Assay), only data about genes included in both panels were considered and only matched primary tumors and recurrences investigated with the same panel could be analyzed. Third, given the retrospective nature of this study including a heterogeneous cohort of patients with breast cancer, we were unable to perform detailed survival analysis or to test the effect of therapy on molecular alterations acquired at progression. Finally, this is an exploratory hypothesis-generating study evaluating the genomic profile of primary breast cancers and breast cancer relapses to investigate inter-tumor genomic heterogeneity. Although the most recurrent driver alterations of primary tumors were detected in matched relapses, we showed that additional and potentially actionable alterations may be detected in the recurrence sample only, as showed by OncoKB levels assessment. Given that we analyzed samples from a retrospective cohort of patients, we could not assess the clinical impact of these findings. However, our data may suggest that inter-tumor genomic heterogeneity of breast cancers might be of clinical relevance and the genomic profile of breast cancer relapses might guide patients tailored treatments. Further ad hoc investigation is needed to confirm our findings and evaluate their clinical impact.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.